GoodRx Holdings Inc. (NASDAQ:GDRX) Stock Update and Financial Overview

Font: Financial Modeling Prep  • Feb 26, 2026

• Leerink Partners maintains an "Outperform" rating for GoodRx Holdings Inc. (NASDAQ:GDRX), indicating potential for above-market performance.
• The stock experienced a significant drop of 18.78% today, now priced at $1.99.
• GoodRx's recent Q4 2025 earnings call provided crucial insights into its financial health, with a focus on earnings, revenue, and profit margins.

GoodRx Holdings Inc. (NASDAQ:GDRX) is a company that provides consumers with information and tools to compare prescription drug prices and find discounts. It operates a platform that aggregates pricing data from various pharmacies, helping users save on their medication costs. GoodRx competes with other healthcare technology companies that offer similar services.

On February 26, 2026, Leerink Partners maintained its "Outperform" grade for GoodRx, with the stock priced at $2.02. This rating suggests confidence in the company's potential to perform better than the market average. However, the stock has since decreased to $1.99, reflecting a drop of 18.78% today, with a change of $0.46.

The recent Q4 2025 earnings call, provided insights into GoodRx's financial performance. The call is an important event for investors, offering a detailed overview of the company's earnings, revenue, and profit margins. Such information is crucial for assessing the company's financial health and future prospects.

GoodRx's stock has seen significant fluctuations, with a 52-week high of $5.81 and a low of $1.92. The current market capitalization is approximately $675.3 million, indicating the total market value of the company's outstanding shares. The trading volume today is 11,549,681 shares, showing active investor interest.

The stock's price movement, with a low of $1.92 and a high of $2.08 today, reflects market volatility. Investors closely monitor these changes to make informed decisions. Despite the recent price drop, the "Outperform" rating from Leerink Partners suggests potential for future growth.